CD8A and hepatocellular carcinoma: treated hepatocellular carcinoma (HCC) with IRE in combination with an anti-PD-L1 monoclonal antibody and found enhanced off-target necrosis and inflammatory infiltration, with IRE significantly increasing the inflammatory infiltration index and increasing CD8+ T infiltration not only in target tissues but also in non-target tissues (untreated tumors) (70).